Skip to main content
Caplight Logo









Paradigm Therapeutics, Inc.

Paradigm Therapeutics, Inc.

Private
Mount Pleasant, South CarolinaHealthcare & Life Scienceshttps://www.paradigmtherapeutics.com/

Last Round

VC Round

Jun 18, 2025

Company Overview

Paradigm Therapeutics, Inc. is a biopharmaceutical company that develops innovative topical therapies for the treatment of rare diseases, specifically Epidermolysis Bullosa.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverybiopharmarare diseaseclinical-stagetherapeutic developmentorphan drugepidermolysis bullosadrug pipelineintellectual property licensingresearch collaborationbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Paradigm Therapeutics, Inc. Comparables

Compare Paradigm Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Paradigm Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CSA Biotechnologies
56%
Mariposa Therapeutics
43%
Aegle Therapeutics Corp
38%

Paradigm Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 18, 2025
VC RoundMay 6, 2025

Paradigm Therapeutics, Inc. Investors

Notable investors and investment history

Paradigm Therapeutics, Inc. investors
InvestorRounds
Eshelman VenturesVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2025

    $13M round led by Eshelman Ventures.

  • May 6, 2025

    $13M round led by Eshelman Ventures

Paradigm Therapeutics, Inc. Filings

Explore SEC and related filing metadata, where available.

Paradigm Therapeutics, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Paradigm Therapeutics, Inc.'s valuation, stock price, and market status.

Is Paradigm Therapeutics, Inc. a public or private company?

Paradigm Therapeutics, Inc. is a private company.

What is the current stock price of Paradigm Therapeutics, Inc.?

Paradigm Therapeutics, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Paradigm Therapeutics, Inc. worth (valuation)?

Valuation information for Paradigm Therapeutics, Inc. is not publicly available.

Can I buy Paradigm Therapeutics, Inc. stock?

Paradigm Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Paradigm Therapeutics, Inc.'s last funding round?

Paradigm Therapeutics, Inc.'s most recent funding round was Series B Extension on June 18, 2025.

Who are the main investors in Paradigm Therapeutics, Inc.?

Key investors in Paradigm Therapeutics, Inc. include Eshelman Ventures.

Will Paradigm Therapeutics, Inc. IPO soon?

No public IPO plans have been announced for Paradigm Therapeutics, Inc..

How can I track Paradigm Therapeutics, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Paradigm Therapeutics, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMount Pleasant, South Carolina
Employee Range5
Year Founded2023
Last FundingJun 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?